NASDAQ:COLL
Collegium Pharmaceutical Stock News
$37.51
+0 (+0%)
At Close: May 03, 2024
Has Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Outpaced Other Medical Stocks This Year?
01:40pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Here is how Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Sanofi's (SNY) Breast Cancer Candidate Misses Goal in Study
04:31pm, Monday, 14'th Mar 2022 Zacks Investment Research
Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.
Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B
04:31pm, Friday, 11'th Mar 2022 Zacks Investment Research
Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.
Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why
04:10pm, Thursday, 10'th Mar 2022 Zacks Investment Research
Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.
Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU
03:49pm, Thursday, 10'th Mar 2022 Zacks Investment Research
Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.
COLL or ZTS: Which Is the Better Value Stock Right Now?
04:40pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
New Strong Buy Stocks for March 3rd
12:48pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
ACGL, ACLS, COLL, SAH, and TGH have been added to the Zacks Rank #1 (Strong Buy) List on March 3, 2022.
New Strong Buy Stocks for March 3rd
09:15am, Thursday, 03'rd Mar 2022
ACGL, ACLS, COLL, SAH, and TGH have been added to the Zacks Rank #1 (Strong Buy) List on March 3, 2022.
Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod
03:04pm, Monday, 28'th Feb 2022 Zacks Investment Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT. Stock declines.
Can Collegium Pharmaceutical (COLL) Climb 30% to Reach the Level Wall Street Analysts Expect?
03:00pm, Monday, 28'th Feb 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.9% in Collegium Pharmaceutical (COLL). While the effectiveness of this highly sought-after metric is questio
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut
04:05pm, Friday, 25'th Feb 2022 Zacks Investment Research
Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni On Q4 2021 Results - Earnings Call Transcript
12:03am, Friday, 25'th Feb 2022 Seeking Alpha
Collegium Pharmaceutical GAAP EPS of -$0.73 misses by $1.08, revenue of $27.36M misses by $54.17M
09:47pm, Thursday, 24'th Feb 2022 Seeking Alpha
Collegium Pharmaceutical press release (COLL): Q4 GAAP EPS of -$0.73 misses by $1.08.Revenue of $27.36M (-64.1% Y/Y) misses by $54.17M.2022 Revenue Guidance of $315-$330 Million,…
Collegium Pharmaceutical, Inc. 2021 Q4 - Results - Earnings Call Presentation
09:35pm, Thursday, 24'th Feb 2022 Seeking AlphaCollegium Pharmaceutical (COLL) Reports Q4 Loss, Lags Revenue Estimates
07:15pm, Thursday, 24'th Feb 2022
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -170.19% and 66.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the
